Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DSGN Design Therapeutics	$2.79 -5.7%	$4.31	$2.66 ▼ $7.77	$158.37M	1.82	208,135 shs	185,368 shs
OCS Oculis	$16.15 -0.6%	$19.33	$10.79 ▼ $23.08	$705.14M	0.19	46,651 shs	37,664 shs
PAHC Phibro Animal Health	$17.72 -7.0%	$22.29	$12.30 ▼ $26.55	$717.71M	0.63	188,625 shs	241,679 shs
XERS Xeris Biopharma	$3.95 -8.8%	$4.38	$1.69 ▼ $6.07	$608.06M	1.37	1.85 million shs	4.24 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DSGN Design Therapeutics	-5.74%	-20.74%	-47.65%	-38.27%	-26.58%
OCS Oculis	-0.55%	-8.19%	-12.23%	-23.64%	+38.27%
PAHC Phibro Animal Health	-7.03%	-12.36%	-21.07%	-11.62%	+33.94%
XERS Xeris Biopharma	-8.78%	-19.06%	-10.02%	+16.18%	+99.49%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DSGN Design Therapeutics	1.2041 of 5 stars	3.3	0.0	0.0	0.0	0.6	2.5	0.6
OCS Oculis	1.931 of 5 stars	3.5	3.0	0.0	0.0	2.6	0.0	0.6
PAHC Phibro Animal Health	4.1953 of 5 stars	1.8	5.0	1.7	1.1	2.9	3.3	2.5
XERS Xeris Biopharma	4.2354 of 5 stars	4.4	1.0	0.0	4.2	3.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DSGN Design Therapeutics	2.50	Moderate Buy	$8.00	186.74% Upside
OCS Oculis	3.00	Buy	$29.50	82.66% Upside
PAHC Phibro Animal Health	1.50	Reduce	$21.00	18.51% Upside
XERS Xeris Biopharma	2.80	Moderate Buy	$6.10	54.43% Upside

Current Analyst Ratings Breakdown

Latest DSGN, PAHC, XERS, and OCS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/13/2025	OCS Oculis	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$37.00 ➝ $41.00
3/13/2025	OCS Oculis	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
3/13/2025	OCS Oculis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $29.00
3/7/2025	XERS Xeris Biopharma	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$5.00 ➝ $6.00
3/7/2025	XERS Xeris Biopharma	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.00 ➝ $6.50
3/7/2025	XERS Xeris Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$3.00 ➝ $4.00
3/7/2025	XERS Xeris Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.60 ➝ $8.00
2/10/2025	PAHC Phibro Animal Health	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underweight ➝ Underweight	$20.00 ➝ $22.00
1/29/2025	XERS Xeris Biopharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $6.00

(Data available from 4/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$4.96 per share	N/A
OCS Oculis	$980K	719.53	N/A	N/A	$2.87 per share	5.63
PAHC Phibro Animal Health	$1.11B	0.65	$1.63 per share	10.87	$6.09 per share	2.91
XERS Xeris Biopharma	$203.07M	2.99	N/A	N/A	($0.05) per share	-79.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DSGN Design Therapeutics	-$66.86M	-$0.88	N/A	N/A	N/A	N/A	-18.01%	-17.38%	5/6/2025 (Estimated)
OCS Oculis	-$98.92M	-$2.31	N/A	N/A	N/A	-8,043.28%	-71.31%	-56.85%	5/14/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.48	36.92	8.44	0.45	1.75%	25.35%	6.21%	5/6/2025 (Estimated)
XERS Xeris Biopharma	-$62.26M	-$0.38	N/A	N/A	N/A	-33.69%	N/A	-17.38%	5/8/2025 (Estimated)

Latest DSGN, PAHC, XERS, and OCS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	XERS Xeris Biopharma	-$0.07	N/A	N/A	N/A	$57.61 million	N/A
3/11/2025	Q4 2024	OCS Oculis	-$0.48	-$0.76	-$0.28	-$0.76	$0.21 million	N/A
3/10/2025	Q4 2024	DSGN Design Therapeutics	-$0.28	-$0.24	+$0.04	-$0.24	N/A	N/A
2/5/2025	Q2 2025	PAHC Phibro Animal Health	$0.40	$0.54	+$0.14	$0.08	$292.26 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
OCS Oculis	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	2.71%	N/A	100.00%	N/A
XERS Xeris Biopharma	N/A	N/A	N/A	N/A	N/A

Latest DSGN, PAHC, XERS, and OCS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/4/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.18%	3/5/2025	3/5/2025	3/26/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DSGN Design Therapeutics	N/A	34.61	34.61
OCS Oculis	0.01	4.02	4.02
PAHC Phibro Animal Health	2.99	3.20	1.37
XERS Xeris Biopharma	N/A	1.79	1.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DSGN Design Therapeutics	56.64%
OCS Oculis	22.30%
PAHC Phibro Animal Health	99.34%
XERS Xeris Biopharma	42.75%

Insider Ownership

Company	Insider Ownership
DSGN Design Therapeutics	31.20%
OCS Oculis	N/A
PAHC Phibro Animal Health	50.07%
XERS Xeris Biopharma	4.56%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DSGN Design Therapeutics	40	56.76 million	38.96 million	Optionable
OCS Oculis	2	43.66 million	N/A	Not Optionable
PAHC Phibro Animal Health	1,860	40.50 million	20.22 million	Optionable
XERS Xeris Biopharma	290	153.94 million	142.28 million	Optionable

DSGN, PAHC, XERS, and OCS Headlines

Recent News About These Companies

Xeris Biopharma (NASDAQ:XERS) Trading Down 6.2% - Here's Why

April 3, 2025 | marketbeat.com

AIGH Capital Management LLC Acquires 389,192 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

March 31, 2025 | marketbeat.com

Xeris Announces Changes to Its Board of Directors

March 28, 2025 | finance.yahoo.com

Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5?

March 27, 2025 | msn.com

Xeris Biopharma (NASDAQ:XERS) Reaches New 1-Year High - Still a Buy?

March 25, 2025 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Has $581,000 Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

March 23, 2025 | marketbeat.com

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Beth Hecht Sells 40,000 Shares

March 22, 2025 | marketbeat.com

Xeris Biopharma (NASDAQ:XERS) Trading Up 4.9% - Here's Why

March 22, 2025 | marketbeat.com

Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?

March 20, 2025 | zacks.com

12 Best Stocks to Invest in for a Stock Market Game

March 20, 2025 | insidermonkey.com

Xeris enters a whole new market for one of its main pharma offerings

March 20, 2025 | chicagobusiness.com

Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game

March 19, 2025 | insidermonkey.com

Calculating The Fair Value Of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

March 18, 2025 | finance.yahoo.com

Xeris Biopharma (NASDAQ:XERS) Sets New 12-Month High - Still a Buy?

March 18, 2025 | marketbeat.com

FDA approves Xeris Biopharma’s sNDA of Gvoke VialDx as gastro diagnostic aid

March 17, 2025 | markets.businessinsider.com

Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid

March 17, 2025 | finance.yahoo.com

Globeflex Capital L P Takes $424,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

March 17, 2025 | marketbeat.com

Xeris Biopharma: Low Risk, Low Excitement Solid Revenue Generator

March 16, 2025 | seekingalpha.com

Xeris Biopharma (NASDAQ:XERS) Sees Unusually-High Trading Volume - Here's What Happened

March 15, 2025 | marketbeat.com

Xeris Biopharma Holdings Share Price (XERS.US)

March 12, 2025 | lse.co.uk

Xeris Biopharma (NASDAQ:XERS) Sets New 1-Year High - Should You Buy?

March 12, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN, PAHC, XERS, and OCS Company Descriptions

Design Therapeutics NASDAQ:DSGN

$2.79 -0.17 (-5.74%)

Closing price 04/10/2025 04:00 PM Eastern

Extended Trading

$2.79 0.00 (0.00%)

As of 04/10/2025 04:20 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Oculis NASDAQ:OCS

$16.15 -0.09 (-0.55%)

Closing price 04/10/2025 04:00 PM Eastern

Extended Trading

$16.14 -0.01 (-0.09%)

As of 04/10/2025 04:05 PM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

Phibro Animal Health NASDAQ:PAHC

$17.72 -1.34 (-7.03%)

Closing price 04/10/2025 04:00 PM Eastern

Extended Trading

$17.72 0.00 (0.00%)

As of 04/10/2025 07:11 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Xeris Biopharma NASDAQ:XERS

$3.95 -0.38 (-8.78%)

Closing price 04/10/2025 04:00 PM Eastern

Extended Trading

$4.08 +0.13 (+3.16%)

As of 04/10/2025 07:52 PM Eastern

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time